SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Cerestat

Item No. 30966

CAS Registry No.: 137160-11-3
Formal Name: N-(3-ethylphenyl)-N-methyl-N′-1-naphthalenyl-guanidine, monohydrochloride
Synonym: CNS 1102
MF: $C_{20}H_{21}N_3$ • HCl
FW: 339.9
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cerestat is supplied as a solid. A stock solution may be made by dissolving the cerestat in the solvent of choice, which should be purged with an inert gas. Cerestat is soluble in the organic solvent DMSO. It is also soluble in water. The solubility of cerestat in DMSO and water is approximately 50 and 100 mM, respectively. We do not recommend storing the aqueous solution for more than one day.

Description

Cerestat is an NMDA receptor antagonist (IC_{50} = 36 nM).[1] It is selective for the NMDA receptor over sigma receptors (IC_{50} = 2,540 nM). Cerestat (1 mg/kg) reduces infarct volume and the number of steps and errors in a foot fault test in a rat model of stroke induced by middle cerebral artery occlusion.[2] It also reduces cortical and striatal neuronal necrosis in a rat model of temporary focal ischemia when administered at a dose of 1.13 mg/kg.[3]

References

1. Reddy, N.L., Hu, L.-Y., Cotter, R.E., *et al*. Synthesis and structure-activity studies of *N*,*N*'-diarylguanidine derivatives. *N*-(1-naphthyl)-*N*'-(3-ethylphenyl)-*N*'-methylguanidine: A new, selective noncompetitive NMDA receptor antagonist. *J. Med. Chem.* **37(2)**, 260-267 (1994).
2. Pitsikas, N., Brambilla, A., Besozzi, C., *et al*. Effects of cerestat and NBQX on functional and morphological outcomes in rat focal cerebral ischemia. *Pharmacol. Biochem. Behav*. **68(3)**, 443-447 (2000).
3. Schäbitz, W.R., Li, F., and Fisher, M. The *N*-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. *Stroke* **31(7)**, 1709-1714 (2000).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM